IL10 and systemic lupus erythematosus: Similarly, in vitro treatment of peripheral blood mononuclear cells from SLE patients with an αCD134 Ab reduces interleukin (IL)-4 and IL-10 and enhances IFNγ production whereas CD134-Ig reduces both Th1 and Th2 cytokines [56].